دورية أكاديمية
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
| العنوان: | Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. |
|---|---|
| المؤلفون: | Kochenderfer, James N, Dudley, Mark E, Kassim, Sadik H, Somerville, Robert P T, Carpenter, Robert O, Stetler-Stevenson, Maryalice, Yang, James C, Phan, Giao Q, Hughes, Marybeth S, Sherry, Richard M, Raffeld, Mark, Feldman, Steven, Lu, Lily, Li, Yong F, Ngo, Lien T, Goy, Andre, Feldman, Tatyana, Spaner, David E, Wang, Michael L, Chen, Clara C, Kranick, Sarah M, Nath, Avindra, Nathan, Debbie-Ann N, Morton, Kathleen E, Toomey, Mary Ann, Rosenberg, Steven A |
| المصدر: | J Clin Oncol ; ISSN:1527-7755 ; Volume:33 ; Issue:6 |
| بيانات النشر: | Atypon |
| سنة النشر: | 2015 |
| المجموعة: | PubMed Central (PMC) |
| الوصف: | T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR). We assessed the safety and efficacy of administering autologous anti-CD19 CAR T cells to patients with advanced CD19(+) B-cell malignancies. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://doi.org/10.1200/JCO.2014.56.2025Test; https://pubmed.ncbi.nlm.nih.gov/25154820Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322257Test/ |
| DOI: | 10.1200/JCO.2014.56.2025 |
| الإتاحة: | https://doi.org/10.1200/JCO.2014.56.2025Test https://pubmed.ncbi.nlm.nih.gov/25154820Test https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322257Test/ |
| حقوق: | © 2014 by American Society of Clinical Oncology. |
| رقم الانضمام: | edsbas.E1F7BD66 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1200/JCO.2014.56.2025 |
|---|